Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia

ClinicalTrials.gov ID: NCT01588522

Public ClinicalTrials.gov record NCT01588522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Dose-Escalation Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 (Calcitriol, USP) in Adult Cancer Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Advanced or Recurrent Disease

Study identification

NCT ID
NCT01588522
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
BPGbio
Industry
Enrollment
28 participants

Conditions and interventions

Interventions

  • Compound 31543 Calcitriol 10 μg/mL Drug
  • Compound 31543 Calcitriol 20 μg/mL Drug
  • Compound 31543 Calcitriol 40 μg/mL Drug
  • Compound 31543 Calcitriol 5 μg/mL Drug
  • Compound 31543 Calcitriol 60 ug/mL Drug
  • Compound 31543 Calcitriol 80 μg/mL Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 16, 2012
Primary completion
Feb 15, 2017
Completion
Feb 15, 2017
Last update posted
May 27, 2025

2012 – 2017

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Los Angeles California 90048
Memorial Sloan-Kettering Cancer Center New York New York 10022

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01588522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 27, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01588522 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →